MedPath

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

Completed
Conditions
Human Papillomavirus Infection
Registration Number
NCT01205412
Lead Sponsor
GlaxoSmithKline
Brief Summary

The purpose of this study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for post-natal check up in the Kingdom of Bahrain.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
552
Inclusion Criteria
  • Women ≥ 20 years of age attending a clinic for routine cervical screening OR
  • Women ≥ 16 years of age presenting for post-natal check-ups
  • Women providing a cervical sample
  • Written informed consent or oral-witnessed thumb printed informed consent obtained from the subject
Exclusion Criteria
  • Referral for abnormal cervical sample at the current visit
  • Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed (Note: Enrolment can be delayed until this condition is resolved)
  • Pregnant women
  • History of hysterectomy
  • Known diagnosis of immunosuppression, or patient on immunosuppressives
  • Having received one or more doses of human papillomavirus vaccine prior to participating in the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalence of any Human Papillomavirus (HPV) deoxyribonucleic acid (DNA) and HPV type distribution among women undergoing cervical sample testing and post-natal check up.Average time frame: 12 months
Secondary Outcome Measures
NameTimeMethod
Behavioural risk factorsDuring visit 1 (day 0)
Awareness of HPV in relation to transmission and cause of cervical cancerAverage time frame: 12 months
Prevalence of any HPV DNA and HPV type distribution among women of different age strata undergoing cervical sample testing and post-natal check up.Average time frame: 12 months

Trial Locations

Locations (1)

GSK Investigational Site

🇧🇭

Manama, Bahrain

GSK Investigational Site
🇧🇭Manama, Bahrain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.